The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 11, 2020

Filed:

Apr. 05, 2018
Applicant:

Ocugen, Inc., Malvern, PA (US);

Inventors:

Shankar Musunuri, Chester Springs, PA (US);

Sandeep Jain, Oak Park, IL (US);

Rasappa Arumugham, Lansdale, PA (US);

Arun K. Upadhyay, West Chester, PA (US);

Matthew Nudell, Lafayette, CO (US);

Gopalam Somasekhar, Collegeville, PA (US);

Assignee:

OCUGEN, INC., Malvern, PA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/517 (2006.01); A61K 9/107 (2006.01); A61K 9/00 (2006.01); A61P 27/04 (2006.01); A61K 47/10 (2017.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); A61K 9/10 (2006.01); A61K 9/06 (2006.01); A61K 31/573 (2006.01); A61K 31/155 (2006.01); A61K 31/4725 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 9/10 (2013.01); A61K 9/1075 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61P 27/04 (2018.01); A61K 31/155 (2013.01); A61K 31/4725 (2013.01); A61K 31/573 (2013.01); A61K 2300/00 (2013.01);
Abstract

The present invention provides a composition comprising two or more of the following pharmaceutically active compounds: (i) an alpha 2 adrenergic agonist; (ii) a corticosteroid; (iii) a lymphocyte function-associated antigen antagonist; (iv) a non-steroidal anti-inflammatory drug (NSAID); (v) a sodium channel blocker; and (vi) an antibiotic, provided at least one of the pharmaceutically active compound is selected from the group consisting of (i) alpha 2 adrenergic agonist and (ii) corticosteroid. The present invention also provides a method for using such composition to treat an eye disorder such as a dry eye syndrome; ocular graft-versus-host-disease; ocular rosacea; allergic conjunctivitis; autoimmune ocular surface disease; thygeson's superficial punctuate keratopathy; herpes zoster keratitis; Stevens-Johnson syndrome; keratitis; conjunctivitis; blepharitis; blepharochalasis; conjunctivochalasis; blepharoconjunctivitis; blepharokeratoconjunctivitis; post-operative inflammation or pain from ocular surgery; scleritis; episcleritis; anterior uveitis; iritis; cyclitis; ocular surface vascular disorder; ulcerative keratitis; photokeratitis; dacryocystitis; eyelid disorder; congenital alacrima; xerophthalmia; dacryoadenitis; vernal keratoconjunctivitis; pinguecula; and/or ocular surface disorder induced by chemical burns, thermal burns, or physical insult to the ocular surface.


Find Patent Forward Citations

Loading…